Remdesivir is currently given intravenously in a hospital setting, but an inhaled version given through a nebulizer will be tested in a trial starting in August.
MONDAY, June 22, 2020 (HealthDay News) -- An inhaled version of the antiviral drug remdesivir will soon be tested outside a hospital setting, Gilead Sciences announced Monday.
Remdesivir, which is made by Gilead, is now being used to treat COVID-19 patients worldwide. Currently, the drug has to be given intravenously through daily infusions in the hospital.
"An inhaled formulation would be given through a nebulizer, which could potentially allow for easier administration outside the hospital, at earlier stages of disease," Gilead chairman and CEO Daniel O'Day said in a company news release.